Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | PLAU | P00749 | 2/20 | 0.45 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.45 |
| ▸ | ELANE | P08246 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL521093 | 0.85 | PKM (0.62) | PKMKMT2ALMNAGAACYP1A2 | |
| SCHEMBL12633753 | 0.83 | KMT2A (0.64) | PKMKMT2ALMNAGAACYP1A2 | |
| SCHEMBL10788934 | 0.81 | POLB (0.52) | PKMKMT2ALMNAGAACYP1A2 | |
| SCHEMBL28856266 | 0.81 | KMT2A (0.62) | PKMKMT2ALMNAGAACYP1A2 | |
| SCHEMBL31052720 | 0.80 | PKM (0.60) | PKMKMT2ALMNAGAACYP1A2 | |
| SCHEMBL21826933 | 0.80 | KMT2A (0.67) | PKMKMT2ALMNAGAACYP1A2 | |
| SCHEMBL26649089 | 0.80 | KMT2A (0.60) | PKMKMT2ALMNAGAACYP1A2 | |
| SCHEMBL1107514 | 0.79 | PKM (0.55) | PKMKMT2ALMNAGAACYP1A2 | |
| SCHEMBL21826406 | 0.77 | LMNA (0.55) | PKMKMT2ALMNAGAACYP1A2 | |
| SCHEMBL31738248 | 0.77 | PKM (0.97) | PKMKMT2ALMNAGAACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935699-B2 | Pyrazole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| EP-2261216-A2 | Pyrazoles as glucokinase activators | F. Hoffmann-La Roche AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| CN-101541756-A | Pyrazoles as glucokinase activators | HOFFMANN LA ROCHE (CH) | 2009-09-23 | — | — | CN | disclosed |
| EP-2046755-A2 | PYRAZOLES AS GLUCOKINASE ACTIVATORS | F. Hoffmann-Roche AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008012227-A2 | PYRAZOLES AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-31 | — | — | WO | disclosed |
| US-20080021032-A1 | Pyrazole glucokinase activators | BERTHEL STEVEN JOSEPH | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021032-A1 | Pyrazole glucokinase activators | GCKR, GCK, GALK1 | PKM 116/4885KMT2A 4296/4885LMNA 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.